Saturday, February 8, 2025

Pfizer to Cut Costs as COVID-19 Vaccine and Antiviral Sales Projected to Drop

Similar articles

Pfizer has outlined a cost-cutting plan for the present year and the next, driven by the projected declines in the sales of its COVID-19 vaccine and antiviral treatments. The U.S. government is returning a significant quantity of the antiviral drug Paxlovid, prompting Pfizer to forecast a $7 billion year-on-year drop in revenue. The sales of its Covid vaccine, Comirnaty, are also projected to be $2 billion lower than previous estimations.

The cost-cutting measures are being implemented to align expenses with Pfizer’s future earnings forecasts. Despite the projected decrease in sales of its COVID-19-related products, Pfizer anticipates that its non-Covid revenue will see an increase of between 6% to 8% this year. This growth is expected to be partly driven by the sales of other drugs in its portfolio.

Subscribe Weekly Market Access News

* indicates required

To further boost its long-term sales and compensate for the anticipated drop in revenue from COVID-19-related products, Pfizer may also look into potential mergers and acquisitions. This strategy could provide opportunities for diversification and expansion into new markets.

Pfizer’s announcement amidst a global trend of decreasing demand for COVID-19 vaccines and treatments. This is largely due to the increased vaccination rates worldwide, reducing the need for further doses.

Various pharmaceutical companies are grappling with similar issues, as they face a decline in the demand for COVID-19 vaccines and treatments. As a result, these companies are now shifting their focus to other areas of their business, aiming to maintain growth and profitability despite the changing market dynamics.

The impact of these cost-cutting measures on Pfizer’s operations and overall financial performance will be closely watched by industry experts and stakeholders. The company’s ability to adapt to the changing landscape and maintain its market position will be crucial in the coming months.

Pfizer’s cost-cutting initiative is a response to the projected decline in sales of its COVID-19-related products. The company plans to align its expenses with future revenue projections, while also exploring potential mergers and acquisitions. Despite the expected sales drop, Pfizer anticipates its non-Covid revenue to grow by 6% to 8% this year. The firm’s adaptation to the changing market dynamics will be instrumental in maintaining its market position.


This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Latest article